DXCM - DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead Bullish Analyst Says | Benzinga
DexCom Inc’s (NASDAQ: DXCM) Stelo Glucose Biosensor System has been approved by the Food and Drug Administration (FDA) as the first over-the-counter (OTC) continuous glucose monitor (CGM).
DexCom’s global total addressable market (TAM) is expanding rapidly, positioning the company for revenue upside, according to RBC Capital Markets.
The DexCom Analyst: Shagun Singh initiated coverage of DexCom with an Outperform rating and price target of $165.
The DexCom Thesis: The San Diego-based company has "a multi-year runway ahead” and appears poised to become one of the ...